LONDON, May 14 (Reuters) - Britain’s medical cost-effectiveness watchdog rebuffed ImClone Systems Inc.'s (IMCL.O: Quote, Profile , Research) Erbitux again on Monday, recommending against its use in combination with radiotherapy for patients with head and neck cancer.
